We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Alkermes plc stands fourth on our list among the most ...

Ireland-based Alkermes has announced positive topline results from the randomized double-blind treatment period of the ...

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alkermes ( (ALKS) ) has shared an update.

Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Alkermes today and set a price target of $42.00. The company’s shares opened today at $28.98. Take advantage of TipRanks Premium at 50% ...

The appeal of a drug-patent dispute that allowed patent owner Alkermes PLC to keep $65.6 million in allegedly improper ...

We expect investors to focus on the sales performance of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

The U.S. Court of Appeals for the Federal Circuit (CAFC) on Friday, July 25, transferred an appeal over an award issued in an ...

A few weeks ago, Bianchis, along York Road, in Montpelier, was crowned Bristol's best restaurant by readers at BristolLive.

A race to develop a new class of drugs could transform treatment for patients with narcolepsy — as well as for patients with ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

Dispatch Bio launched with $216 million – backed primarily by Parker Institute for Cancer Immunotherapy, founded by entrepreneur Sean Parker, and ARCH Venture Partners. SAB BIO announced an ...